نتائج البحث - "glucagon like peptide‐1 receptor agonists"

العلاقة: urn:issn:1751-2433; urn:issn:1751-2441; https://orbi.uliege.be/handle/2268/312538Test; info:hdl:2268/312538; scopus-id:2-s2.0-85174726601; info:pmid:37919944

الإتاحة: https://doi.org/10.1080/17512433.2023.2279193Test
https://orbi.uliege.be/handle/2268/312538Test

View record in BASE

5

DataSheet_1_First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis.docx

المؤلفون: Rui Deng, Kaibo Mei, Tiangang Song, Jinyi Huang, Yifan Wu, Peng Yu, Zhiwei Yan, Xiao Liu

مصطلحات موضوعية: Endocrinology, Reproduction, Cell Metabolism, sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, type 2 diabetes, metformin, meta-analysis

العلاقة: https://figshare.com/articles/dataset/DataSheet_1_First-line_treatment_with_sodium-glucose_cotransporter_2_inhibitors_and_glucagon-like_peptide-1_receptor_agonists_in_type_2_diabetic_population_at_low_risk_of_cardiovascular_disease_a_meta-analysis_docx/25104047Test

الإتاحة: https://doi.org/10.3389/fendo.2024.1289643.s001Test
https://figshare.com/articles/dataset/DataSheet_1_First-line_treatment_with_sodium-glucose_cotransporter_2_inhibitors_and_glucagon-like_peptide-1_receptor_agonists_in_type_2_diabetic_population_at_low_risk_of_cardiovascular_disease_a_meta-analysis_docx/25104047Test

View record in BASE

6

DataSheet_1_Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.docx

المؤلفون: Wei Chen, Peishan Cai, Wenbin Zou, Zhiwen Fu

مصطلحات موضوعية: Endocrinology, Reproduction, Cell Metabolism, glucagon-like peptide-1 receptor agonists, psychiatric adverse events, disproportionality analyses, FAERS database, pharmacovigilance study

العلاقة: https://figshare.com/articles/dataset/DataSheet_1_Psychiatric_adverse_events_associated_with_GLP-1_receptor_agonists_a_real-world_pharmacovigilance_study_based_on_the_FDA_Adverse_Event_Reporting_System_database_docx/25188077Test

الإتاحة: https://doi.org/10.3389/fendo.2024.1330936.s001Test
https://figshare.com/articles/dataset/DataSheet_1_Psychiatric_adverse_events_associated_with_GLP-1_receptor_agonists_a_real-world_pharmacovigilance_study_based_on_the_FDA_Adverse_Event_Reporting_System_database_docx/25188077Test

View record in BASE

7

DataSheet_1_Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.docx

المؤلفون: Qingyue Zeng, Jiao Xu, Xingyu Mu, Yi Shi, Hong Fan, Shuangqing Li

مصطلحات موضوعية: Endocrinology, Reproduction, Cell Metabolism, dual agonists, incretin based therapy, tirzepatide, type 2 diabetes, obesity, glucagon-like peptide-1 receptor agonists

العلاقة: https://figshare.com/articles/dataset/DataSheet_1_Safety_issues_of_tirzepatide_pancreatitis_and_gallbladder_or_biliary_disease_in_type_2_diabetes_and_obesity_a_systematic_review_and_meta-analysis_docx/25407643Test

الإتاحة: https://doi.org/10.3389/fendo.2023.1214334.s001Test

View record in BASE

8

Table_1_Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.xlsx

المؤلفون: Qingyue Zeng, Jiao Xu, Xingyu Mu, Yi Shi, Hong Fan, Shuangqing Li

مصطلحات موضوعية: Endocrinology, Reproduction, Cell Metabolism, dual agonists, incretin based therapy, tirzepatide, type 2 diabetes, obesity, glucagon-like peptide-1 receptor agonists

العلاقة: https://figshare.com/articles/dataset/Table_1_Safety_issues_of_tirzepatide_pancreatitis_and_gallbladder_or_biliary_disease_in_type_2_diabetes_and_obesity_a_systematic_review_and_meta-analysis_xlsx/25407646Test

الإتاحة: https://doi.org/10.3389/fendo.2023.1214334.s002Test

View record in BASE

9

Changes in the use of glucose‐lowering drugs: A Danish nationwide study

المؤلفون: Jacob Andersen, Anton Pottegård, Reimar Thomsen, Jens Sondergaard, Tina VilsbÃ¸ll

المصدر: Pottegård, A, Andersen, J H, Søndergaard, J, Thomsen, R W & Vilsbøll, T 2023, ' Changes in the use of glucose-lowering drugs : A Danish nationwide study ', Diabetes, Obesity and Metabolism, vol. 25, no. 4, pp. 1002-1010 . https://doi.org/10.1111/dom.14947Test

مصطلحات موضوعية: glucagon-like peptide-1 receptor agonists, sodium-glucose co-transporter-2 inhibitors, pharmacoepidemiology, Endocrinology, antidiabetics, Endocrinology, Diabetes and Metabolism, Internal Medicine, glucose-lowering medication, type 2 diabetes, drug utilization

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d302e561a55856ce8a81559d7088166Test
https://doi.org/10.1111/dom.14947Test

10

Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes

المؤلفون: Max Nieuwdorp, Richard G. IJzerman, Hiddo J.L. Heerspink, Annemarie B van der Aart-van der Beek, Daniël H. van Raalte, Klaas Hoogenberg, Charlotte C. van Ruiten

المساهمون: Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Groningen Kidney Center (GKC), Experimental Vascular Medicine, Vascular Medicine, ACS - Diabetes & metabolism, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Internal medicine, Amsterdam Gastroenterology Endocrinology Metabolism, AGEM - Endocrinology, metabolism and nutrition

المصدر: Diabetes, Obesity and Metabolism, 23(8), 1851-1858. Wiley
Diabetes, obesity & metabolism, 23(8), 1851-1858. Wiley-Blackwell
Diabetes, Obesity and Metabolism, 23(8), 1851-1858. Wiley-Blackwell
van Ruiten, C C, van der Aart-van der Beek, A B, IJzerman, R G, Nieuwdorp, M, Hoogenberg, K, van Raalte, D H & Heerspink, H J L 2021, ' Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial ', Diabetes, Obesity and Metabolism, vol. 23, no. 8, pp. 1851-1858 . https://doi.org/10.1111/dom.14410Test
Diabetes, Obesity & Metabolism

مصطلحات موضوعية: medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, exenatide, Urology, Renal function, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Kidney, Placebo, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Endocrinology, Double-Blind Method, Glucosides, Internal Medicine, medicine, Humans, glucagon‐like peptide‐1 receptor agonists, Obesity, Benzhydryl Compounds, Dapagliflozin, glucagon-like peptide-1 receptor agonists, Creatinine, business.industry, Original Articles, GLP‐1RA, dapagliflozin, medicine.disease, GLP-1RA, Confidence interval, diabetic kidney disease, Clinical trial, Diabetes Mellitus, Type 2, chemistry, Original Article, business, Exenatide, SGLT2 inhibitors, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db634e9eacb798bab746cd9b0bbe03a3Test
https://research.rug.nl/en/publications/59bdca93-36c4-452f-9139-f7df36899868Test

تنقيح النتائج